Medlicott returns to fill e-Therapeutics FD role
Steve Medlicott, who advised the pharmacology company in 2012, returns to serve as FD
Steve Medlicott, who advised the pharmacology company in 2012, returns to serve as FD
THE CFO of drug discovery and development company e-Therapeutics has resigned, with a former adviser stepping into the role.
Dr Daniel Elger has left the listed UK pharmacology business with immediate effect. In a stock exchange statement earlier this morning, e-Therapeutics announced that its financial controller will hold the interim FD role, however, it then followed up an hour later with another statement announcing Steve Medlicott as FD.
Medlicott, a PwC-trained chartered accountant, advised the company during its fundraising in 2013. He has served in a range of business development and sell-side roles, with Peel Hunt, N+1 Singer, Altium Capital and Williams de Broe. He has also served as director of finance at Waste2Tricity.
Professor Malcolm Young, chief executive of e-Therapeutics, said: “We are excited to welcome Steve to the company as our finance director. He has unsurpassed knowledge and understanding of the financial markets and of e-Therapeutics, having supported us to raise funds in 2013. His capabilities and experience will be very valuable to us.”
The Oxford- and Newcastle-based biotech business recently provided encouraging news around its anti-cancer drug trials, which saw analyst Edison Group restate its positive rating on its shares.
Leave a Reply
You must be logged in to post a comment.